{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chronic-kidney-disease/background-information/prognosis/","result":{"pageContext":{"chapter":{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis","depth":2,"htmlHeader":"<!-- begin field 5eb6d0a8-7bdf-43c5-b9eb-d657d612f60f --><h2>What is the prognosis?</h2><!-- end field 5eb6d0a8-7bdf-43c5-b9eb-d657d612f60f -->","summary":"","htmlStringContent":"<!-- begin item faa0a3e9-4756-4a33-9a96-27061109a8dd --><!-- begin field c97b9e57-3863-4f59-9f67-07419dcb3970 --><p><strong>Decreasing estimated glomerular filtration rate (eGFR) and/or increasing proteinuria are independently associated with a poorer prognosis of chronic kidney disease (CKD) </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">NICE, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Vassalotti, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Webster, 2017</a>]<strong>.</strong></p><ul><li>A UK retrospective longitudinal cohort study of data from more than 400 primary care practices in the General Practice Research Database in 2010 found the prevalence of CKD stages 3–5 was 5.9%. Of these [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Jameson, 2014</a>]:<ul><li>Disease progressed by one CKD stage in about 10–15% of people.</li><li>Disease remained stable in about 50% of people.</li><li>Disease improved in about 25–30% of people.</li></ul></li><li>A smaller UK 5-year prospective cohort study of 32 primary care practices of people with CKD stage 3 (n = 1741) found that at the end of the study period disease outcomes were heterogenous [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Shardlow, 2016</a>]:<ul><li>14.2% of people had died from all causes, and 5.4% specifically from cardiovascular causes.</li><li>0.2% of people had developed end-stage renal disease (ESRD).</li><li>17.7% of people had progressive disease.</li><li>34.1% of people had stable disease.</li><li>19.3% of people were in remission with no evidence of CKD.</li><li>Note: the study population was predominantly elderly (mean age 72.9 years) and Caucasian, so the results may not be directly applicable to the general population.</li></ul></li><li>End-stage renal disease (ESRD).<ul><li>People are at increased risk if they have <a class=\"topic-reference internal-reference\" href=\"/topics/chronic-kidney-disease/management/management-of-chronic-kidney-disease/#monitoring-disease-progression\">accelerated progression</a> of CKD.</li><li>Over a 5-year period, less than 2% of people with CKD will progress to need renal replacement therapy (dialysis or kidney transplantation) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Webster, 2017</a>].</li><li>An Italian cohort study (n = 27,642) found the five-year relative survival of people with ESRD on long-term dialysis was 55% compared with age-matched controls in the general population. Older age, co-morbid systemic disease and diabetes mellitus showed the strongest association with excess mortality [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Nordio, 2012</a>].</li></ul></li><li>All-cause mortality.<ul><li>A US systematic review of 39 cohort studies or cohort analyses of non-dialysis patients with CKD (n = 1, 371, 990) found the unadjusted relative risk for mortality in people with CKD compared with those without ranged from 0.94 to 5.0, and was significantly more than 1.0 in 93% of cohorts. The absolute risk for death increased exponentially with declining renal function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Tonelli, 2006</a>].</li><li>In a Swedish population-based cohort study of people with CKD stages 4–5 (n = 3040), the mortality hazard ratio was 3.6 compared with age- and sex-matched controls in the general population [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Neovius, 2014</a>].</li><li>People with CKD are 5–10 times more likely to die than to progress to ESRD. The mortality risk rises with CKD disease progression, and is largely due to cardiovascular disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/chronic-kidney-disease/references/\">Webster, 2017</a>].</li></ul></li></ul><!-- end field c97b9e57-3863-4f59-9f67-07419dcb3970 --><!-- end item faa0a3e9-4756-4a33-9a96-27061109a8dd -->","topic":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8","topicId":"ae266062-cc1b-44e2-8118-44e1890750e3","topicName":"Chronic kidney disease","slug":"chronic-kidney-disease","lastRevised":"Last revised in May 2020","chapters":[{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b4e7fb9-e75e-5183-b93f-5121d902b8aa","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"75479619-9bb3-51b1-8d45-322a0183327c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes"},{"id":"e9caee39-e4d7-55ea-bba5-d1bfb037fab3","slug":"update","fullItemName":"Update"}]},{"id":"94be5ea4-6a52-53bd-9cff-cbc58599fb38","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"af9d912d-8cc7-598f-90cf-201a0152486f","slug":"goals","fullItemName":"Goals"},{"id":"e04a2acd-d3aa-5b29-afe8-4ff8a5cf2527","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c36c8ae1-59b3-5370-8b7b-c879c1c25d17","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb64e97-bb95-5733-ba72-d5da80477d5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0cefa383-4a3f-5e37-8c1d-0cc7b2ba971c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c308ef71-7be3-579d-9b92-dd1e9164c74d","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"420f2db7-0bb3-5f08-a35d-671ffd9e83db","slug":"definition","fullItemName":"Definition"},{"id":"f36e5c98-76d5-563f-b7e3-a8e580d8edda","slug":"causes","fullItemName":"Causes"},{"id":"16745b88-79f5-5576-a0a4-704c8cb342e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82584375-f9fb-5690-9fe3-f2fb2586f2de","slug":"complications","fullItemName":"Complications"},{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00dbd4ad-decc-5bde-b4a3-2599d730c702","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"cdd9f22d-7a2f-5fd6-a9e1-199b0c3ffdfa","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c6b6c8c3-633d-5062-9804-7b6711e7ddcd","slug":"assessment","fullItemName":"Assessment"},{"id":"3878fa85-9973-5158-8407-20d64dbf148d","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"579baee5-96e6-5639-a5ee-7dc30540dc8f","fullItemName":"Management","slug":"management","subChapters":[{"id":"07ec0bcd-8fb7-5ae7-87fd-2ff471574c5c","slug":"management-of-chronic-kidney-disease","fullItemName":"Scenario: Management of chronic kidney disease"},{"id":"44ceaa7d-a91b-5472-a7ab-e4bc448067ad","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs"}]},{"id":"50985320-3b22-5997-85d2-680285318de6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"168ee77d-eb0d-52d8-a32b-4bda877d21f0","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c8ca80a7-ccf2-5a42-9b8e-72783e1f2131","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fe26a3ba-fa1b-5c97-8a08-e1f7d193447a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"854a26b2-4877-59ae-863e-99abcbcad667","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0af4d212-648e-5a4d-ad67-b1874a49688e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f180e32d-a855-558d-b666-d4c6804afe04","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ba009e6c-4065-55da-b6c5-bd179af81374","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}